Advancing Genomic Research
- Furthering investigation that leads to scientific advances and new insights and therapies for patients with neurodegenerative disease, neuropsychiatric disease, and cancer
- Leveraging our strengths in whole genome sequencing, genomic analysis, and development of genomic tools
Serving as a Nexus for Collaboration
- Harnessing the combined strengths of our faculty, member institutions, scientific working groups, affiliate members, and industry partners
- For the New York scientific community and beyond
Leading Collaborative Research in Neurodegenerative Disease
Building on the success of NYGC’s global consortium for ALS research to drive discovery for conditions with common disease pathways, including dementia, Alzheimer’s disease, frontotemporal dementia, Parkinson’s disease, and Huntington’s disease.
Expanding Understanding of Neuropsychiatric Disease
Leveraging our large-scale whole genome research of autism patients to related disorders that have commonly implicated genes, such as schizophrenia and bipolar disorder
Focusing on whole genome sequencing of individuals with cancer and their tumors, novel population-level cancer analytics, and the application of both single cell sequencing and spatial transcriptomics
The New York Genome Center (NYGC) is an independent, nonprofit academic research institution focused on furthering genomic research that leads to scientific advances and new insights and therapies for patients with neurodegenerative disease, neuropsychiatric disease, and cancer, leveraging our strengths in whole genome sequencing, genomic analysis, and development of genomic tools.
We serve as a nexus for collaboration in genomic research for the New York community and beyond, building on the combined strengths of our faculty, member institutions, scientific working groups, affiliate members, and industry partners.
Central to this commitment is an outstanding faculty who are leading independent research labs based at the NYGC and one of our member institutions. They also support the NYGC scientific mission and engage in research programs that support the NYGC and the wider scientific community.
To learn more about NYGC,
read our A Year in Review 2018.
IN THE NEWS
GoT: New Tool Further Dissects Cancer Complexity
GoT, or Genotyping of Transcriptomes, is a new genomic method developed in a research collaboration jointly supervised at the New York Genome Center (NYGC) by Core Faculty Member Dan Landau, MD, PhD, who holds a joint appointment at Weill Cornell Medicine, and Peter Smibert, PhD, head of NYGC’s Technology Innovation Lab. The tool allows for targeted detection of specific mutations of interest in combination with the transcriptome of the same cell. The method has important implications for investigating cells within genetically heterogeneous populations, such as tumors.
IN THE NEWS
New York Genome Center Receives $125M Gift
The joint gift from the Simons Foundation and The Carson Family Charitable Trust, to be awarded over the next five years, supports the NYGC’s efforts to build and maintain the genomic infrastructure required to work with its institutional founding members to establish transformative collaborative research programs in neurodegenerative and neuropsychiatric diseases and cancer.
Developing New Genomic Tools & Technologies
Our scientists are focused on collaborative initiatives in single cell and spatial transcriptomics and the computational methods necessary to understand the underlying biology and disease mechanisms.
Our Technology Innovation Lab is a leader in developing new technologies for enhanced single-cell analysis, including CITE-seq, Cell Hashing, and ECCITE-seq, and making them widely accessible to the scientific community.
Furthering Scientific Inquiry
Our outstanding faculty and staff scientists are recognized as innovators in the field, and in the last five years have published over 200 papers in leading scientific journals helping to advance genomic science. They have received many awards and honors, including three prestigious NIH New Innovator Awards. Their important research has provided new insights, including the discovery of dozens of new genes that create cancer resistance and hundreds of genes that impact the human immune system. NYGC researchers have also contributed to uncovering new genetic signatures for autism, the identification of a novel gene associated with ALS, and a better understanding of the mechanisms and progression of ALS.